MTOR and non-small cell lung carcinoma: Thus, miR-23a could be a potential target for overcoming resistance to EGFR-TKIs in NSCLC.22 In addition, there are several miRNAs that target the PI3K/AKT/mTOR pathways that have shown promising antitumor efficacy and the ability to reverse EGFR-TKIs resistance.